{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:11:31Z","timestamp":1771931491015,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The rising antibiotic resistance has significantly reduced the efficacy of standard bismuth-based quadruple therapy for\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic>H. pylori<\/jats:italic>\n                      ) infections, particularly in patients with multiple eradication failures. This study evaluates a novel non-antibiotic triple therapy comprising Weisu granules, berberine hydrochloride, and Bio-Three\u2014a probiotic formulation containing\n                      <jats:italic>Clostridium butyricum<\/jats:italic>\n                      TO-A,\n                      <jats:italic>Enterococcus faecalis<\/jats:italic>\n                      T-110, and\n                      <jats:italic>Bacillus mesentericus<\/jats:italic>\n                      TO-A\u2014in treating\n                      <jats:italic>H. pylori<\/jats:italic>\n                      -positive functional dyspepsia (FD) patients resistant to conventional antibiotic treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      A two-center retrospective analysis involved 48 FD patients who had previously failed at least two\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication therapies. Participants underwent a 14-day course of non-antibiotic therapy, with primary endpoints being\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication rate, assessed via 14C urea breath test, and secondary endpoints including symptom relief and adverse reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Successful\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication was achieved in 72.9% (35\/48) of patients. Symptom relief was observed in 77.08% of cases, with 43.75% achieving effective improvement and 33.33% marked improvement. Adverse reactions were mild, occurring in 8.3% (4\/48) of patients, including abdominal distension, dry mouth, and nausea, all resolving spontaneously. The compliance rate was high at 91.67%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study provides preliminary evidence supporting the use of non-antibiotic triple therapy as an alternative for managing\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infections in FD patients resistant to conventional antibiotic treatments, demonstrating notable eradication rates and symptom relief with minimal adverse effects. Further research is warranted to explore its mechanisms, long-term efficacy, and potential integration into existing treatment paradigms.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1759043","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:04:24Z","timestamp":1770793464000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel non-antibiotic triple therapy for Helicobacter pylori-positive functional dyspepsia patients resistant to conventional antibiotic treatments: an exploratory pilot study"],"prefix":"10.3389","volume":"13","author":[{"given":"Canyu","family":"Zhan","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]},{"name":"Department of Gastroenterology, Xingyi People's Hospital","place":["Xingyi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]},{"name":"Department of Gastroenterology, Liupanshui Municipal People's Hospital","place":["Liupanshui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangliu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gengqing","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Metrohealth Medical Center, Case Western Reserve University","place":["Cleveland, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University","place":["Guiyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1136\/gutjnl-2020-320839","article-title":"Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis","volume":"69","author":"Ford","year":"2020","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMra1501505","article-title":"Functional dyspepsia","volume":"373","author":"Talley","year":"2015","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1053\/gast.2002.36024","article-title":"Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection","volume":"123","author":"Berc\u00edk","year":"2002","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"gutjnl-2021-326583","DOI":"10.1136\/gutjnl-2021-326583","article-title":"Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis","volume":"71","author":"Ford","year":"2022","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/jcm8091324","article-title":"Helicobacter pylori eradication therapy for functional dyspepsia: a meta-analysis by region and H. pylori prevalence","volume":"8","author":"Kang","year":"2019","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin Med J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.13241\/j.cnki.pmb.2021.14.016","article-title":"Effects of gastric Su granules combined with quadruple therapy on serum inflammatory factors, gastrointestinal hormones, and quality of life in patients with Helicobacter pylori-associated peptic ulcer","volume":"21","author":"Hu","year":"2021","journal-title":"Adv Mod Biomed"},{"key":"ref13","first-page":"650","article-title":"Study on the effect of gastric Su granules combined with triple bactericidal therapy in treating patients with Helicobacter pylori infection","volume":"34","author":"Tan","year":"2023","journal-title":"Mod Diagn Treatment"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s11684-019-0724-6","article-title":"Biological properties and clinical applications of berberine","volume":"14","author":"Song","year":"2020","journal-title":"Front Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jconrel.2020.09.025","article-title":"Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori","volume":"328","author":"Shen","year":"2020","journal-title":"J Control Release"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/1751-2980.13146","article-title":"Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori","volume":"23","author":"Chen","year":"2022","journal-title":"J Dig Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/ijms21031136","article-title":"Using probiotics as supplementation for Helicobacter pylori antibiotic therapy","volume":"21","author":"Ji","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1620870","DOI":"10.3389\/fphar.2025.1620870","article-title":"Beyond antibiotics: probiotics as a promising ally against Helicobacter pylori","volume":"16","author":"Yuan","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/biomedicines10020483","article-title":"Effect of Clostridium butyricum on gastrointestinal infections","volume":"10","author":"Ariyoshi","year":"2022","journal-title":"Biomedicine"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e22976","DOI":"10.1097\/MD.0000000000022976","article-title":"The efficacy and safety of clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment: An open-label, single-arm pilot study","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.3760\/cma.j.issn.0376-2491.2022.22.102","article-title":"A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China","volume":"11","author":"Zhong","year":"2021","journal-title":"Am J Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e12714","DOI":"10.1111\/hel.12714","article-title":"The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis","volume":"25","author":"Zou","year":"2020","journal-title":"Helicobacter"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3748\/wjg.v29.i2.390","article-title":"Third-line and rescue therapy for refractory Helicobacter pylori infection: a systematic review","volume":"29","author":"de Moraes Andrade","year":"2023","journal-title":"World J Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/pathogens11070786","article-title":"Primary antibiotic resistance of Helicobacter pylori in different regions of China: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2022","journal-title":"Pathogens"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/07853890.2022.2031269","article-title":"The prospective multiple-Centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas","volume":"54","author":"Shen","year":"2022","journal-title":"Ann Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e12970","DOI":"10.1111\/hel.12970","article-title":"Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China","volume":"28","author":"Hu","year":"2023","journal-title":"Helicobacter"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e12918","DOI":"10.1111\/hel.12918","article-title":"Eradication rate and safety of a \"simplified rescue therapy\": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: a real-world, retrospective clinical study in China","volume":"27","author":"Gao","year":"2022","journal-title":"Helicobacter"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3969\/j.issn.1002-2694.2019.00.092","article-title":"Drug susceptibility and pbp1 diversity analysis of 351 Helicobacter pylori strains in Guiyang","volume":"35","author":"Wu","year":"2019","journal-title":"Chinese J Hum Vet Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/1751-2980.12432","article-title":"Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: a systematic review and meta-analysis","volume":"17","author":"Gao","year":"2016","journal-title":"J Dig Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5626235","DOI":"10.1155\/2022\/5626235","article-title":"TCM-based therapy as a rescue therapy for re-eradication of Helicobacter pylori infection: a systematic review and meta-analysis","volume":"2022","author":"Zhong","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3000605231203841","DOI":"10.1177\/03000605231203841","article-title":"Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review and meta-analysis","volume":"51","author":"Yao","year":"2023","journal-title":"J Int Med Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"21501327211014087","DOI":"10.1177\/21501327211014087","article-title":"Treatment approach of refractory Helicobacter pylori infection: a comprehensive review","volume":"12","author":"Cort\u00e9s","year":"2021","journal-title":"J Prim Care Community Health"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1756284821989177","DOI":"10.1177\/1756284821989177","article-title":"The status and progress of first-line treatment against Helicobacter pylori infection: a review","volume":"14","author":"Liu","year":"2021","journal-title":"Ther Adv Gastroenterol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1759043\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:23:29Z","timestamp":1771928609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1759043\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":33,"alternative-id":["10.3389\/fmed.2026.1759043"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1759043","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1759043"}}